Dataset Information

Integrated DIA proteomics and lipidomics analysis on non-small cell lung cancer patients with TCM syndromes

ABSTRACT: Lung cancer remains the leading cause of mortality from malignant tumors, non-small cell lung cancer (NSCLC) accounts for the majority of lung cancer cases, and individualized diagnosis and treatment in traditional Chinese Medicine (TCM) is an effective trend. In this study, a proteomics research with DIA mode and a non-targeted lipidomics research were developed in NSCLC patients with Qi deficiency and Yin deficiency (QDYD) and Qi deficiency of lung-spleen (QDLS) syndromes.

ORGANISM(S): Homo Sapiens

SUBMITTER: Qing Li

PROVIDER: PXD024704 | iProX | Fri Sep 24 00:00:00 BST 2021

REPOSITORIES: iProX

ACCESS DATA

Publications

Integrated DIA proteomics and lipidomics analysis on non-small cell lung cancer patients with TCM syndromes.

Cang Song S Liu Ran R Jin Wei W Tang Qi Q Li Wanjun W Mu Kunqian K Jin Pengfei P Bi Kaishun K Li Qing Q

Chinese medicine 20211127 1

<h4>Background</h4>Lung cancer remains the leading cause of mortality from malignant tumors, non-small cell lung cancer (NSCLC) accounts for the majority of lung cancer cases, and individualized diagnosis and treatment is an effective trend. The individual characteristics of different traditional Chinese medicine (TCM) syndromes of NSCLC patients may be revealed by highly specific molecular profiles.<h4>Methods</h4>In this study, 10 NSCLC patients with Qi deficiency and Yin deficiency (QDYD) syn ...[more]

PMID: 34838074

Similar Datasets

Project description:<p><strong>OBJECTIVES:</strong> High activity of Indoleamine 2,3-dioxygenase1 (IDO1) in lung cancer patients converts tryptophan (Trp), which is the essential amino acid for T cell metabolism, to kynurenine (Kyn) and consequently suppresses anti-tumor immune responses. We aimed to track the dynamics of IDO1 activity in stage III non-small cell lung cancer (NSCLC) patients who received first-line radiotherapy (RT) and explore its association with survival outcomes.</p><p><strong>MATERIALS AND METHODS:</strong> Systemic IDO1 activity was calculated by Kyn:Trp ratio. Plasma levels of Kyn and Trp in 113 thoracic RT-received stage III NSCLC patients were measured by high-performance liquid chromatography before the initiation of RT. Dynamic change of IDO1 activity was followed in 24 patients by measuring Kyn:Trp ratio before, during and after RT administration.</p><p><strong>RESULTS:</strong> In 24 patients with dynamic tracking of plasma IDO1 activity, there was no significant alterations observed among the 3 time points (Friedman test, p=0.13). The changing pattern of Kyn:Trp ratio was divided into 4 groups: decreased consistently during RT, first increased then decreased, increased consistently, first decreased then increased. Patients whose Kyn:Trp ratio kept decreasing or first increased then decreased were defined as good-change group. The good-change status was identified as an independent positive factor for overall survival (OS) and progression-free survival (PFS) (p=0.04; p=0.01) in multivariate analysis among evaluated parameters. Patients with good change showed significantly superior local control than bad-change group (p=0.01, HR=0.22). In 113 stage III NSCLC patients with pre-radiation Kyn:Trp ratio, a trend that high baseline IDO1 activity was associated with short OS was observed (p=0.079).</p><p><strong>CONCLUSION: </strong>Favorable change of IDO1 activity during RT was associated with superior OS, PFS and local control. IDO1 activity is a promising biomarker for prognosis in stage III NSCLC patients.</p>

Dataset Information

Integrated DIA proteomics and lipidomics analysis on non-small cell lung cancer patients with TCM syndromes

Publications

Integrated DIA proteomics and lipidomics analysis on non-small cell lung cancer patients with TCM syndromes.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure